William H. Sharfman

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

Life Sciences, Immunology, Oncology +17

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer, Charles G. Drake, Ira Wollner et al. · Journal of Clinical Oncology · 2010 · 2.9K citations · Full text

Medicine, Oncology, Pharmacology +17

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov et al. · Cell · 2017 · 2.6K citations · Full text

Medicine, Immunology, Oncology +12

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Suzanne L. Topalian, Mario Sznol, David F. McDermott et al. · Journal of Clinical Oncology · 2014 · 2.2K citations

Life Sciences, Immunology, Oncology +17

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Paul Nghiem, Shailender Bhatia, Evan J. Lipson et al. · New England Journal of Medicine · 2016 · 1.2K citations · Full text

Medicine, Dermatology, Oncology +17